Z-321,99.55%
产品编号:Bellancom-19123| CAS NO:130849-58-0| 分子式:C19H24N2O2S| 分子量:344.47
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Z-321
产品介绍 | Z-321 是一个脯氨酰内肽酶 (PEP) 抑制剂。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Z-321 is a prolylendopeptidase (PEP) inhibitor. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
Z-321 is a prolylendopeptidase (PEP) inhibitor. In the 100 or 200 mg/kg Z-321-treated groups, mean lordosis quotient (LQ) decreases after administration. However, there is no statistical difference among the values before and after. In contrast, the mean LQ in the 300 mg/kg Z-321-treated females is lower than that before injection (P<0.005). Furthermore, when compare to that in the vehicle-treated control group, mean LQ is also significantly lower (p<0.05). The incidence of soliciting behavior decreases after treatment with 300 mg/kg Z-321, when compare to that before treatment, but there is no statistical difference. The present study also demonstrates that 300 mg/kg Z-321 is effective in inhibiting lordosis behavior without disturbance of locomotor activity. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
Z-321 is a prolylendopeptidase (PEP) inhibitor. In the 100 or 200 mg/kg Z-321-treated groups, mean lordosis quotient (LQ) decreases after administration. However, there is no statistical difference among the values before and after. In contrast, the mean LQ in the 300 mg/kg Z-321-treated females is lower than that before injection (P<0.005). Furthermore, when compare to that in the vehicle-treated control group, mean LQ is also significantly lower (p<0.05). The incidence of soliciting behavior decreases after treatment with 300 mg/kg Z-321, when compare to that before treatment, but there is no statistical difference. The present study also demonstrates that 300 mg/kg Z-321 is effective in inhibiting lordosis behavior without disturbance of locomotor activity. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 250 mg/mL (725.75 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |